CYP1B1

Across TCGA pan-cancer cohorts, CYP1B1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYP1B1 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CYP1B1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CYP1B1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where CYP1B1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	39	view →
PDAC	OS	Quartile	II,III,IV	0.410	0.672	.012	6	view →
UCEC	DFS	Median	II,III,IV	0.543	0.882	.041	4	view →
LUAD	DFS	Quartile	All	0.744	0.477	.023	3	view →
LSCC	DFS	Median	II,III,IV	1.000	0.419	.008	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYP1B1–CCRCC (DFS)

Open the CCRCC breakdown →